At Silicon Therapeutics, we use physics driven approaches to create lasting therapeutic and target franchises to impact human disease.
July 7, 2018
Silicon Therapeutics Announces Prof. David Mobley as Open Science Fellow
Boston – July 2, 2018: Silicon Therapeutics, an integrated computational drug discovery company creating novel small molecule therapeutics for diseases with challenging protein targets, is pleased to announce that Dr. David Mobley of the University of California at Irvine (UCI) has been named an Open Science Fellow. Prof. Mobley is focused on applying computational and theoretical methods to understand fundamental biological processes such as protein-ligand binding, solvation, and solubility. The Open Science Fellow program is designed to support investigators who have demonstrated a commitment to the open science movement through their contributions to open source software.
“Open science is an integral part of the culture at Silicon Therapeutics, and Prof. Mobley has clearly demonstrated a commitment to this philosophy through his numerous contributions to open source software and community datasets,” said Dr. Woody Sherman, CSO at Silicon Therapeutics. ”Prof. David Mobley is an emerging leader in biomolecular simulations – he has made significant contributions in the areas of free energy simulations, solubility predictions, and force field development. We look forward to working closely with Prof. Mobley to further advance the field and make cutting-edge simulation tools more accessible to the scientific community.”
“I’m delighted to be working with Silicon Therapeutics and the broader research community on open science and open source software,” said Dr. Mobley. “I am convinced that the free energy simulation work we are doing together will show great utility for molecular design and I’m excited to be part of this effort to advance the science in our field.”
About Dr. David Mobley
Dr. David Mobley focuses on applying computational and theoretical methods to understand and quantitatively predict fundamental biological processes such as protein-ligand binding, solvation, and solubility. He seeks to provide an atomically detailed understanding of these processes at a level of accuracy that can be useful in industrial applications. Prof. Mobley did his undergraduate work in Physics at the University of California at Davis (UCD), graduating in 2000. After that he finished a M.S. (2002) and a Ph.D. (2004) in Physics at UCD, doing graduate research in condensed matter theory and biophysics with Daniel L. Cox and Rajiv Singh. Following his Ph.D. he took a position with Ken Dill at the University of California, San Francisco, doing molecular simulations relating to protein-ligand binding and hydration thermodynamics. He joined the University of New Orleans (UNO) as a faculty member in Fall 2008. Then, in 2012, he moved to at the University of California, Irvine (UCI) and is now a tenured professor in the departments of Pharmaceutical Sciences and Chemistry and head of the Mobley Lab. He served on the scientific advisory board for Schrödinger software from 2013-2016. He currently serves on the editorial board of the Journal of Computer-Aided Molecular Design and on the scientific advisory board for OpenEye Scientific Software.
Silicon Therapeutics, the first fully integrated physics-driven drug discovery company, is focused on developing novel medicines for diseases with targets that are currently considered to be challenging for traditional approaches. Our platform closely represents the real dynamic nature of targets using accurate all-atom simulations, enabling us to gain deep insights into the biomolecular recognition process associated with targets that were previously considered “undruggable.” Our science, our team, and our mission are focused on applying advanced physics-based computational technologies to build and progress a pipeline of innovative medicines for patients. Silicon Therapeutics is headquartered in Boston, MA, USA with offices in Shanghai, China. Learn more at www.silicontx.com